Compare Marriott International Inc (MAR) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marriott International Inc vs TransMedics Group Inc — how do they compare? Marriott International Inc trades at $365.88 (market cap $94.16B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Marriott International Inc is far larger — about 34.4× TransMedics Group Inc's market cap, and Marriott International Inc pays a 0.81% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marriott International Inc for 164 Days and TransMedics Group Inc for 24 Days on average.
| MAR | TMDX | |
|---|---|---|
Market Cap | $94.16B | $2.74B |
Volume | 996,176 | 949,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $150.42 |
52-Week Low | $259.04 | $61.99 |
Typical Hold Time | 164 Days | 24 Days |
Enterprise Value | $111.47B | $3.13B |
Dividend Yield | 0.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $361.08, up 1.28% with bullish technical signals and strong institutional support. The company shows steady revenue growth to $26.19B in 2025 with a 9.62% net margin, though valuation metrics appear elevated with a P/E of 37.38. Recent earnings beat expectations in Q1 and Q2 2026, while analysts maintain a consensus price target of $386.71 with 44% buy ratings.
MAR presents growth potential through travel recovery and strategic partnerships, but faces risks from high debt levels (58.83% debt-to-asset ratio) and economic sensitivity. The stock's technical strength and fundamental growth support a positive outlook, though investors should monitor debt management and macroeconomic impacts on travel demand.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
